日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted therapy

将新型4D放射组学应用于动态FES PET图像,以提高对乳腺癌ER靶向治疗反应的预测能力

Chen, Andrew William; Zeballos Torrez, Carla R; Peterson, Lanell M; Muzi, Mark; Specht, Jennifer M; Cohen, Eric A; Linden, Hannah M; Kontos, Despina; Mankoff, David A

Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)

视觉和计算机评估的肿瘤浸润淋巴细胞在早期三阴性乳腺癌中的预后价值(TBCRC-030)

Nader-Marta, Guilherme; Chu, Xiangying; Mukhopadhyay, Satabhisa; Abramson, Vandana G; Brufsky, Adam; Stringer-Reasor, Erica Michelle; Dent, Susan Faye; Traina, Tiffany A; Carey, Lisa A; Rimawi, Mothaffar F; Specht, Jennifer M; Miller, Kathy D; Santa-Maria, Cesar Augusto; Dasgupta, Tathagata; Kurt, Busem Binboğa; DeMeo, Michelle; Krop, Ian E; Tung, Nadine M; Schnitt, Stuart J; Tayob, Nabihah; Mayer, Erica L

Incidental discovery of second primary lung tumors in breast cancer patients: an institutional case series

乳腺癌患者意外发现第二原发性肺肿瘤:一项机构病例系列研究

Iancu, Alexandra; Gwin, William; Vinayak, Shaveta; Linden, Hannah M; Specht, Jennifer; Symonds, Lynn; Davidson, Nancy; Hunter, Natasha

The Role of Estrogen Receptor-Targeted PET with 16α-(18)F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis

16α-(18)F-氟-17β-雌二醇靶向雌激素受体PET在预测转移性乳腺癌内分泌治疗反应中的作用:一项荟萃分析

Specht, Jennifer M; van Geel, Jasper J L; Song, Shaoli; Liu, Cheng; Hippe, Daniel S; DiGregorio, Nicholas A; Brand, Christine J; Linden, Hannah M

Patient and Physician Perspectives on Using Risk Prediction to Support Breast Cancer Surveillance Decision Making

患者和医生对利用风险预测支持乳腺癌监测决策的看法

Gunn, Christine M; Boyer, Nancy; Sheikh, Sidra; Lee, Janie M; Woloshin, Steven; Specht, Jennifer M; Hubbard, Rebecca A; Bowles, Erin J Aiello; Su, Yu-Ru; Tosteson, Anna N A

TILseg: Automated Whole Slide-Level Spatial Scoring of Tumor-Infiltrating Lymphocytes Reveals Prognostic Patterns in Triple Negative Breast Cancer

TILseg:肿瘤浸润淋巴细胞的自动化全切片空间评分揭示三阴性乳腺癌的预后模式

Carr, Lisa L; Sankaranarayanan, Abishek; Ha, Khanh; Rawlani, Meenal; Kazerouni, Anum S; Specht, Jennifer; Kennedy, Laura C; Reiter, Daniel; Dintzis, Suzanne; Hippe, Daniel S; Kilgore, Mark R; Symonds, Lynn; Partridge, Savannah C; Mittal, Shachi

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

BASECAMP-1 筛选研究:精准肿瘤临床试验高效入组的模式

Hecht, J Randolph; Molina, Julian R; Liechty, Kirstin; Welling, Theodore H; Grierson, Patrick M; Patel, Sandip P; Kirtane, Kedar; Morelli, M Pia; Locke, Frederick L; Maloney, David G; Punekar, Salman R; Nikiforow, Sarah; Lin, Yi; Ulrickson, Matthew; Specht, Jennifer M; Lozac'hmeur, Ariane; Osterman, Chelsea K; Garde, Ryan J; Rangel, Gena A; Ng, Eric W; Welch, John S; Tebbets, Jessica C; Go, William Y; Simeone, Diane M

Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

格达托利西布联合帕博西尼和来曲唑治疗既往未接受过全身治疗的激素受体阳性、HER2阴性晚期乳腺癌患者

Wesolowski, Robert; Rugo, Hope S; Specht, Jennifer M; Han, Hyo S; Kabos, Peter; Vaishampayan, Ulka; Wander, Seth A; Gogineni, Keerthi; Spira, Alexander; Schott, Anne F; Abu-Khalaf, Maysa; Mutka, Sarah C; Suzuki, Samuel; Sullivan, Brian; Gorbatchevsky, Igor; Layman, Rachel M

A composite (18)F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)

一种基于 (18)F-FDG PET/CT 和 HER2 组织的复合生物标志物,用于预测 HER2 阳性乳腺癌对新辅助帕妥珠单抗和曲妥珠单抗的反应 (TBCRC026)

Hennessy, Maeve A; Cimino-Mathews, Ashley; Carter, Jodi M; Kachergus, Jennifer M; Ma, Yaohua; Leal, Jeffrey P; Solnes, Lilja B; Abramson, Vandana G; Carey, Lisa A; Rimawi, Mothaffar; Specht, Jennifer; Storniolo, Anna Maria; Vaklavas, Christos; Krop, Ian; Winer, Eric; Denbow, Rita; Valero, Vincente; Wolff, Antonio C; Wahl, Richard L; Huang, Chiung-Yu; Stearns, Vered; Thompson, E Aubrey; Connolly, Roisin M

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer

氟雌二醇 (FES) 和氟代脱氧葡萄糖 (FDG) PET 显像在 ER+、HER2 阳性或 HER2 阴性转移性乳腺癌患者中的应用

Hunter, Natasha B; Peterson, Lanell M; Specht, Jennifer M; Mankoff, David A; Muzi, Mark; Chen, Delphine L; Gwin, William R; Vinayak, Shaveta; Davidson, Nancy E; Linden, Hannah M